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Summary
Background Artemisinin-combination therapy (ACT) is recommended as ﬁ rst-line treatment of falciparum malaria 
throughout the world, and ﬁ xed-dose combinations are preferred by WHO; whether a single gametocytocidal dose of 
primaquine should be added is unknown. We aimed to compare eﬀ ectiveness of four ﬁ xed-dose ACTs and a loose tablet 
combination of artesunate and meﬂ oquine, and assess the addition of a single gametocytocidal dose of primaquine.
Methods In an open-label randomised trial in clinics in Rakhine state, Kachin state, and Shan state in Myanmar 
(Burma) between Dec 30, 2008, and March 20, 2009, we compared the eﬀ ectiveness of all four WHO-recommended 
ﬁ xed-dose ACTs (artesunate–meﬂ oquine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, artemether–
lumefantrine) and loose artesunate–meﬂ oquine in Burmese adults and children. Eligible patients were those who 
presented to the clinics with acute uncomplicated Plasmodium falciparum malaria or mixed infection, who were older 
than 6 months, and who weighed more than 5 kg. Treatments were randomised in equal numbers within blocks of 50 
and allocation was in sealed envelopes. All patients were also randomly assigned to receive either a single dose of 
primaquine 0·75 mg base/kg or not. Patients were followed up for 63 days. Treatment groups were compared by 
analysis of variance and multiple logistic regression. The primary outcome was the 63 day recrudescence rate. This 
study is registered with clinicaltrials.gov, number NCT00902811.
Findings 155 patients received artesunate–amodiaquine, 162 artemether–lumefantrine, 169 artesunate–meﬂ oquine, 
161 loose artesunate–meﬂ oquine, and 161 dihydroartemisinin–piperaquine. By day 63 of follow-up, 14 patients (9·4%; 
95% CI 5·7–15·3%) on artesunate–amodiaquine had recrudescent P falciparum infections, a rate signiﬁ cantly higher 
than for artemether–lumefantrine (two patients; 1·4%; 0·3–5·3; p=0·0013), ﬁ xed-dose artesunate–meﬂ oquine 
(0 patients; 0–2·3; p<0·0001), loose artesunate–meﬂ oquine (two patients; 1·3%; 0·3–5·3; p=0·0018), and dihydro-
artemisinin–piperaquine (two patients 1·3%; 0·3–5·2%; p=0·0012). Hazard ratios for re-infection (95% CI) after 
artesunate–amodiaquine were 3·2 (1·3–8·0) compared with the two artesunate–meﬂ oquine groups (p=0·01), 2·6 
(1·0–6–0) compared with artemether–lumefantrine (p=0·04), and 2·3 (0·9–6·0) compared with dihydroartemisinin–
piperaquine (p=0·08). Mixed falciparum and vivax infections were common: 129 (16%) had a mixed infection at 
presentation and 330 (41%) patients had one or more episodes of Plasmodium vivax infection during follow-up. The 
addition of a single dose of primaquine (0·75 mg/kg) reduced P falciparum gametocyte carriage substantially: rate ratio 
11·9 (95% CI 7·4–20·5). All regimens were well tolerated. Adverse events were reported by 599 patients, most 
commonly vomiting and dizziness. Other side-eﬀ ects were less common and were not related to a speciﬁ c treatment.
Interpretation Artesunate–amodiaquine should not be used in Myanmar, because the other ACTs are substantially 
more eﬀ ective. Artesunate–meﬂ oquine provided the greatest post-treatment suppression of malaria. Adding a single 
dose of primaquine would substantially reduce transmission potential. Vivax malaria, not recurrent falciparum 
malaria, is the main complication after treatment of P falciparum infections in this region. 
Funding Médecins sans Frontières (Holland) and the Wellcome Trust Mahidol University Oxford Tropical Medicine 
Research Programme.
Introduction
Artemisinin-based combination therapy (ACT) is 
recommended by WHO for the treatment of uncomplicated 
falciparum malaria.1 The success of this recent policy 
change will depend on the eﬃ  cacy of the combination 
components, high population coverage, low costs, correct 
dosing, and ensuring good adherence to prescribed 
treatment. To improve adherence and acceptability, and 
prevent one drug being taken without its partner, ACTs 
are preferably formulated in ﬁ xed-dose combinations.2–5 
Four ﬁ xed-dose ACTs are now available: two new 
combinations (artesunate–meﬂ oquine and artesunate–
amodiaquine) now join artemether–lumefantrine and 
dihydroartemisinin–piperaquine.
Artemisinin and its derivatives reduce gametocyte 
carriage,6 but they do not prevent transmission from 
gametocytaemia present at the time of treatment.7 A 
single gametocytocidal dose of primaquine was widely 
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recommended in low transmission areas before the 
introduction of ACTs.8 With the greater eﬀ ects of 
artemisinins on gametocyte carriage there has been 
uncertainty whether primaquine should be added to ACT 
regimens.9 This question is of increasing importance as 
countries move from malaria control to elimination, 
which will require eﬀ ective, well tolerated medicines and 
reduction of transmission.
Our aim was to compare the eﬃ  cacy of the four 
available ﬁ xed-dose ACTs and the currently used loose 
tablet combination of artesunate with meﬂ oquine and to 
assess the eﬀ ectiveness of adding a single gametocytocidal 
dose of primaquine.
Methods
Patients
Between Dec 30, 2008, and March 20, 2009, we recruited 
patients into our open-label randomised study at three 
clinics in Rakhine state in western Myanmar (Burma),2,3,4,10 
two clinics in Kachin state in northern Myanmar, and 
one clinic in Shan state in northeast Myanmar. Patients 
older than 6 months who weighed more than 5 kg and 
presented with acute uncomplicated Plasmodium 
falciparum malaria (parasite density 500–200 000 parasites 
per μL) or mixed infection were enrolled into the study 
after fully informed consent was obtained from them or 
their carer. Patients were excluded if they were pregnant, 
had severe malaria, had severe acute malnutrition 
(weight-for-height below 70% of median with or without 
symmetrical peripheral oedema), had taken antimalarial 
drugs within the past 48 h, had taken meﬂ oquine during 
the past 9 weeks, or had known history of hypersensitivity 
to any of the study drugs.
Randomisation
After patients were screened and enrolled into the study, 
they were stratiﬁ ed prospectively into three age groups 
(1–4 years, 5–14 years, and older than 14 years). Patients 
were randomly assigned in equal numbers to receive 
one of the ﬁ ve diﬀ erent treatments. They were then 
randomly assigned either a single dose of primaquine 
0·75 mg base/kg (Government Pharmaceutical 
Organisation, Bangkok, Thailand) or not. Treatment 
allocations were put in sealed envelopes in blocks of 
50 for each age-group, and random assignment was 
achieved by patients drawing an envelope from a box 
after enrolment. When the box was empty, another 
50 envelopes were added.
Procedures
For the four ﬁ xed-dose combinations the standard dosage 
instructions of the manufacturer for weight and age 
ranges were followed. For the loose tablets regimen of 
artesunate plus meﬂ oquine, the target dose was 
artesunate 4 mg/kg per day for 3 days (total 12 mg/kg) 
plus meﬂ oquine 25 mg base/kg on day 0; the number of 
pills given was rounded oﬀ  to the nearest quarter of a 
tablet. For ﬁ xed dose artesunate–meﬂ oquine 
hydrochloride we used 25 mg plus 55 mg or 100 mg plus 
220 mg tablets, the target dose was 4·0 mg/kg per day 
plus 8·8 mg/kg per day for 3 days. For ﬁ xed-dose 
artemether–lumefantrine we used 20 mg plus 120 mg 
tablets twice daily for 3 days, the target dose was 
3·3 mg/kg per day plus 19·8 mg/kg per day; patients 
were advised to consume some fatty food (or mothers 
were encouraged to breastfeed treated infants) before 
each dose. For ﬁ xed-dose dihydroartemisinin–
piperaquine we used 40 mg plus 320 mg or 20 mg plus 
160 mg tablets, the target dose was 2·5 mg/kg per day 
plus 20 mg/kg per day. For ﬁ xed dose artesunate–
amodiaquine we used 25 mg plus 67·5 mg, 50 mg plus 
135 mg, or 100 mg plus 270 mg tablets, the target dose 
was 4 mg/kg per day plus 10·8 mg base/kg per day.
The ﬁ rst dose was taken under supervision. For children, 
tablets were crushed and syrup was added. All subsequent 
doses were self administered. Patients received sealed 
plastic bags containing the remaining doses and were 
instructed clearly about their subsequent treatment, 
emphasising the importance of taking primaquine after 
food, and taking their medicines even when their 
symptoms had subsided. Patients were asked to return 
weekly for 9 weeks for assessment, and at any other time 
if they became ill. Microscopists examining blood ﬁ lms 
were unaware of treatment allocation. Haemoglobin was 
measured on day 63.
Patients with recurrent falciparum malaria were treated 
with artesunate–meﬂ oquine (loose tablets). Patients who 
had already received this treatment were given 
dihydroartemisinin–piperaquine. PCR genotyping was 
used to distinguish recrudescence from re-infection, by 
assessment of variable blocks within merozoite surface 
proteins 1 and 2, and glutamate-rich protein.11
Patients who developed intercurrent Plasmodium vivax 
or Plasmodium malariae infections received chloroquine 
(25 mg base/kg) and continued follow-up. If the patients 
were again positive for P vivax 14 days or later, they were 
retreated with chloroquine and deﬁ ned as having a new 
P vivax episode (as a result of treatment failure, relapse, 
or, less likely, a new infection).
Statistical analysis
A sample size of 160 patients (80 with primaquine) per 
study group (total 800 patients) allowed a cure rate 
(100–recrudescence rate) of 95% per group to be estimated 
with 5% precision, and allowed estimation of eﬀ ectiveness 
equivalence with a maximum allowable diﬀ erence of 10% 
(90% power and 95% conﬁ dence) between groups with a 
follow-up drop-out rate of up to 20%.
Treatment groups were compared by two-way factor 
analysis: ANOVA for continuous variables and multiple 
logistic regression for categorical data. A test for trend 
was used for comparisons across age groups. Time-to-
event outcomes, including time to ﬁ rst recurrence (vivax 
or falciparum), time to recrudescence (new infections 
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censored), and time to new infection (recrudescent 
infections censored) were assessed by the Kaplan-Meier 
method. Patients lost to follow-up were censored at the 
last time seen. When failure rates were zero, CIs were 
estimated with the exact binomial method with the 
eﬀ ective sample size. All other treatments were 
compared against the current standard of care, which is 
artesunate plus meﬂ oquine (loose tablets), and then 
against ﬁ xed-dose artesunate–meﬂ oquine hydrochloride, 
with the log-rank test, or the Wilcoxon-Breslow test of 
equality if survival lines crossed. Cox regression was 
used to quantify risks.
Person-gametocyte weeks (PGW) were deﬁ ned as the 
number of weeks in which gametocytaemia was patent 
(excluding at admission) divided by the duration of 
follow-up, expressed per 1000 person-weeks. The 
protocol was approved by the Myanmar Department of 
Health and by the Médecins sans Frontières ethics 
review board. This study is registered with clinicaltrials.
gov, number NCT00902811.
Figure 1: Trial proﬁ le
AA=artesunate–amodiaquine. PQ=primaquine. DP=dihydroartemisinin–piperaquine. AL=artemether–lumefantrine. AM-L=loose tablet regimen of artesunate–meﬂ oquine. 
AM-F=ﬁ xed-dose artesunate–meﬂ oquine.
   155 AA (71 with PQ, 84 no PQ)
           17 <5 years
           56 5–14 years
           82 >14 years
28 664 patients screened
         5 lost to follow-up
   162 AL (78 with PQ, 84 no PQ)
            17 <5 years
            60 5–14 years
            85 >14 years
         9 lost to follow-up
   169 AM-F (86 with PQ, 83 no PQ)
            18 <5 years
            63 5–14 years
            88 >14 years
         7 lost to follow-up
    161 AM-L (79 with PQ, 82 no PQ)
             18 <5 years
             57 5–14 years
             86 >14 years
      12 lost to follow-up
   161 DP (83 with PQ, 78 no PQ)
            17 <5 years
            62 5–14 years
            82 >14 years
         6 lost to follow-up
    3 excluded from the study 
        due to laboratory error
  811 randomly assigned to treatment group
27 853 ineligible
               16 436 no malaria
                     633 parasitaemia outside range
                        72 gametocytes only
                  8103 P vivax only
                          4 pregnant
                  2605 refused consent
     
      150 analysed on day 63       153 analysed on day 63       162 analysed on day 63       149 analysed on day 63       155 analysed on day 63
AA AL AM-F AM-L DP
Number of patients 155 162 169 161 161
Primaquine single dose 71 78 86 79 83
Women 55 (36%) 44 (27%) 62 (37%) 52 (32%) 50 (31%)
Age groups (years)
1–4 17 (11%) 17 (11%) 18 (11%) 18 (11%) 17 (11%)
5–14 56 (36%) 60 (37%) 63 (37%) 57 (35%) 62 (39%)
>14 82 (53%) 85 (53%) 88 (52%) 86 (53%) 82 (51%)
Mean haemoglobin g/dL (SD) 11·3 (0·26) 11·4 (0·27) 11·5 (0·25) 11·5 (0·26) 11·3 (0·24)
Anaemic (haemoglobin <10 g/dL) 48 (31%) 54 (33%) 46 (27%) 48 (30%) 50 (31%)
Geometric mean parasite count per 
μL (range)
7077 (521–163 881) 8709 (557–151 714) 7934 (554–177 000) 7849 (504–139 600) 7879 (546–176 000)
Mixed infections 26 (17%) 25 (15%) 21 (12%) 31 (19%) 26 (16%)
Gametocytaemia on admission 53 (34%) 54 (33%) 50 (30%) 46 (29%) 61 (38%)
AA=artesunate–amodiaquine. AL=artemether–lumefantrine. AM-F=artesunate–meﬂ oquine ﬁ xed-dose combination. AM-L=artesunate–meﬂ oquine loose tablets. 
DP=dihydroartemisinin–piperaquine.
Table 1: Baseline characteristics
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Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Figure 1 shows the trial proﬁ le. Of the patients screened 
for malaria, 3416 met the inclusion criteria. Most of the 
patients that did not agree to participate did so because 
they lived too far away from the study clinic. 713 of the 
patients who were randomly assigned to a treatment 
group were from Rakhine state, 66 were from Kachin 
state, and 32 were from Shan state. Three patients were 
excluded after random assignment because they were 
incorrectly reported as positive for P falciparum on day 7 
and so were treated again. Of the 808 eligible patients, 
397 (49·1%) also received primaquine (ﬁ gure 1). All 
patients survived, although 39 (4·9%) did not complete 
the 63 day follow-up. Baseline characteristics were similar 
among the ﬁ ve treatment groups (table 1). Table 2 shows 
the median (IQR) and range of doses received.
All patients cleared parasitaemia by day 7. 69 patients 
had recurrence of P falciparum within 63 days (table 3). 
Recurrence was less common in patients in the ﬁ xed-
dose artesunate–meﬂ oquine group than in the ﬁ xed-dose 
artesunate–amodiaquine group, ﬁ xed-dose artemether–
lumefantrine group, and the ﬁ xed-dose dihydro-
artemisinin–piperaquine group but was not signiﬁ cantly 
diﬀ erent to that in the loose tablet artesunate–meﬂ oquine 
recipients (table 3, ﬁ gure 2). Thus recurrence was less 
common in the two artesunate–meﬂ oquine groups 
combined than in the other ACT groups (for artesunate–
amodiaquine p<0.0001, for artemether–lumefantrine 
p=0.0097, and for dihydroartemisinin–piperaquine 
p=0.02). Recurrence of P falciparum parasitaemia was 
signiﬁ cantly (p=0·011) more common in children 
younger than 5 years (13 [15%] of 87 children) than in 
those aged 5–14 years (28 [9%] of 298), or in adults 
(28 [7%] of 423).
38 new infections and 20 recrudescent parasitaemias 
occurred by day 63. Results for nine patients were 
indeterminate (two artesunate–amodiaquine, three 
artemether–lumefantrine, three dihydroartemisinin–
piperaquine, and one loose tablet artesunate–meﬂ oquine), 
and data for two patients (one artesunate–amodiaquine 
and one loose artesunate–meﬂ oquine) were missing. If 
indeterminate or missing results are treated as censored 
ﬁ ndings, then the treatment failure rate after ﬁ xed-dose 
artesunate–amodiaquine was signiﬁ cantly higher than for 
the other treatments (for ﬁ xed-dose artesunate–meﬂ oquine 
p<0·0001, for artesunate–meﬂ oquine loose p=0·0018, for 
artemether–lumefantrine p=0·0013, and for dihydro-
artemisinin–piperaquine p=0·0012; table 3). If 
indeterminate or missing results are treated as failures, 
then failure rates after ﬁ xed-dose artesunate–meﬂ oquine 
(0%; 95% CI 0–2·3) were signiﬁ cantly lower than those for 
other treatments (for artesunate–amodiaquine [11·3%; 
95% CI 7·2–17·5] p<0·0001, for artesunate–meﬂ oquine 
loose [2·7%; 1·0–7·0] p=0·0355, for artemether–
lumefantrine [3·4%; 1·4–7·95] p=0·0191, and for dihydro-
artemisinin–piperaquine [3·3%; 1·4–7·65] p=0·0207) and 
failure rates after ﬁ xed-dose artesunate–amodiaquine were 
signiﬁ cantly higher than with the other regimens; ﬁ xed-
dose artemether–lumefantrine (p=0·0042), the loose tablet 
regimen of artesunate–meﬂ oquine (p=0·0025), ﬁ xed-dose 
artesunate–meﬂ oquine (p<0·0001), and ﬁ xed-dose 
dihydro artemisinin–piperaquine (p=0·004). If chloroquine 
treatment of intercurrent vivax malaria had any signiﬁ cant 
antimalarial eﬀ ect it would have reduced late cases of 
recrudescence. Chloroquine did not aﬀ ect cure rates except 
Number by day 28; 
proportion (95% CI)
Number by day 63; 
proportion (95% CI)
Median days to 
event (IQR); range
p value for 
day 63 
comparison 
with AM-L
p value for 
day 63 
comparison 
with AM-F
Recurrence of P falciparum
AA 16; 10·5 (6·6–16·6) 28; 18·6 (13·2–25·8) 28 (17·5–42); 14–63 0·001 <0·0001
AL 5; 3·2 (1·3–7·4) 15; 9·7 (6·0–15·6) 42 (21–56); 14–63 0·09 0·01
AM-F 0; 0 (0–2·2) 5; 3·1 (1·3–7·2) 42 (35–56); 35–63 0·43 ··
AM-L 2; 1·3 (0·3–5·2) 7; 4·7 (2·3–9·7) 42 (28–56); 14–56 ·· 0·43
DP 5; 3·2 (1·3–7·4) 14; 9·0 (5·4–14·7) 38·5 (28–56); 14–63 0·14 0·02
Recrudescent P falciparum infections*
AA 12; 8·0 (4·6–13·6) 14; 9·4 (5·7–15·3) 21 (14–28); 14–49 0·002 0·0001
AL 1; 0·6 (0·1–4·5) 2; 1·4 (0·3–5·3) 42 (21–63); 21–63 0·95 0·14
AM-F 0; 0·0 (0–2·2) 0; 0 (0–2·3) ·· 0·14 ··
AM-L 1; 0·6 (0·1–4·5) 2; 1·3 (0·3–5·3) 31·5 (14–49); 14–49 ·· 0·14
DP 0; 0·0 (0–2·3) 2; 1·3 (0·3–5·2) 38·5 (35–42); 35–42 0·96 0·14
Re-infections with P falciparum†
AA 2; 1·4 (0·3–5·5) 11; 8·2 (4·6–14·3)  42 (35–63); 21–63 0·02 0·05
AL 3; 1·9 (0·6–5·8) 10; 6·5 (3·6–11·8) 38·5 (28–49); 14–63 0·05 0·13
AM-F 0; 0·0 (0–2·2) 5; 3·1 (1·3–7·2)    42 (35–56); 35–63 0·58 ··
AM-L 0; 0·0(0–2·5) 3; 2·1 (0·7–6·4)    56 (42–56); 42–56 ·· 0·58
DP 3; 1·9 (0·6–5·8) 9; 5·9 (3·1–11·1) 49 (28–56); 21–63 0·09 0·21
AM-F=artesunate–meﬂ oquine ﬁ xed-dose combination. AM-L=artesunate–meﬂ oquine loose tablets. AA=artesunate–
amodiaquine. AL=artemether–lumefantrine. DP=dihydroartemisinin–piperaquine. *PCR indeterminate and new 
infections censored. †Recrudescent and indeterminate parasitaemias censored.
Table 3: Recurrence of Plasmodium falciparum after antimalarial treatment
Total target 
doses (mg/kg)
Median (IQR; range)
Artesunate–meﬂ oquine 
(loose)
12/25 12 (11·7– 12·2; 10·7–14·2); 25 (24·5–25·3; 22·3–29·5)
Artesunate–meﬂ oquine 
(ﬁ xed dose)
12/26·4 14·6 (12·5– 16·7; 7·0– 30·0); 32·2 (27·5– 36·7; 15·5–66·0)
Artemether–lumefantrine 9·9/59·4 10·9 (9·8– 12·0; 7·9– 16·0); 65·4 (58·8– 72·0; 47·2–96·0)
Dihydroartemisinin–
piperaquine
7·5/60 7·3 (6·5– 8·4; 4·4– 16·0); 58·2 (51·7– 67·4; 35·3–128·0)
Artesunate–amodiaquine 12/32·4 12·3 (10·7–14·3; 8·6–16·7); 33·1 (28·9–38·6; 23·2–45·0)
Primaquine 0·75 0·76 (0·7–0·82; 0·53–1·07)
Table 2: Drug doses given
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in the ﬁ xed-dose artesunate–amodiaquine group: there 
were two cases of recrudescence in the 59 (4·6%; 1·2–8·0) 
who did not receive chloroquine versus 12 of 96 (13·2%; 
7·7–22·0) who did (p=0·04). Primaquine did not aﬀ ect 
recrudescence rates.
The risk of new infection was more than three-times 
higher for patients who received artesunate–amodiaquine 
compared with the artesunate–meﬂ oquine groups 
combined (hazard ratio [HR] 3·2; 95% CI 1·3–8·0; p=0·01) 
and more than twice that with artemether–lumefantrine 
(2·6; 1·0–6·6; p=0·04) and dihydroartemisinin–
piperaquine (2·3; 0·9–6·0; p=0·08).
129 patients (16%) had mixed infections at presentation, 
and these were more common in children (102 [27%] of 
385) than in adults (27 [6%] of 423; risk ratio  [RR] 4·2, 
95% CI 2·8–6·2; p<0·0001). All patients with mixed 
infections responded to ACT treatment. 330 patients had 
P vivax infection during follow-up (ﬁ gure 3): 259 had one 
episode (68 had mixed infections initially), 55 had two, 
and three had three. Thus the 330 patients had 
404 episodes of P vivax during follow-up. Of the 
679 patients presenting with P falciparum infections only, 
235 (35%) had subsequent P vivax malaria compared 
with 95 (74%) of those with mixed infection initially 
(p<0·0001). Fewer cases of P vivax were recorded in 
patients who received ﬁ xed-dose artesunate–meﬂ oquine 
than in patients who received ﬁ xed-dose artesunate–
amodiaquine, ﬁ xed-dose artemether–lumefantrine, or 
the loose tablet regimen of artesunate plus meﬂ oquine 
(table 4). The median time to the identiﬁ cation of P vivax 
was 35 days after ﬁ xed-dose artemether–lumefantrine, 
42 days after the loose tablet regimen of artesunate plus 
meﬂ oquine, 49 days after ﬁ xed-dose artesunate–
amodiaquine and ﬁ xed-dose artesunate–meﬂ oquine, and 
56 days after ﬁ xed-dose dihydroartemisinin–piperaquine 
(p=0·0001). Thus 12 of the 14 cases of recrudescence of 
P falciparum infection after artesunate–amodiaquine 
happened before the median time to P vivax relapse for 
this group (table 2), which argues against a major eﬀ ect 
of chloroquine in suppressing recrudescence. The 
median time to P vivax recurrence was shorter for 
children aged 0–14 years (42 days; IQR 35–56) than for 
adults (56; 42–63; p=0·0001). Children were nearly three 
times more likely to develop intercurrent vivax malaria 
than were adults, after adjusting for treatment and mixed 
infections at admission (HR 2·91; 95% CI 2·28–3·70; 
p<0·0001). Single-dose primaquine did not aﬀ ect P vivax 
rates (data not shown).
Pooling all recurrences of falciparum or vivax malaria 
together provided a combined measure of eﬃ  cacy and 
post-treatment prophylaxis, and it also addresses any 
possible confounding by weak activity of chloroquine 
against recrudescent P falciparum, because patients 
were censored at the time of any recurrence of malaria. 
The day 63 malaria-free rate was highest in the ﬁ xed-
dose artesunate–meﬂ oquine (64·3%; 95% CI 56·4–71·1) 
and the dihydroartemisinin–piperaquine (55·5%, 
47·2–63·1) groups. The other three treatment groups 
had malaria-free rates of less than 50%, and all were 
signiﬁ cantly worse than ﬁ xed-dose artesunate–
meﬂ oquine (artesunate–amodiaquine HR 1·86, 95% CI 
1·32–2·62; artemether–lumefantrine 2·46, 1·77–3·43; 
and the loose tablet regimen of artesunate plus 
meﬂ oquine 1·79, 1·28–2·52).
264 patients (33%) presented with patent 
gametocytaemia, which was more common in children 
younger than 5 years (46 [53%] of 87) than in children 
Figure 2: Comparative eﬃ  cacy of the ﬁ ve ACT regimens against falciparum malaria in Myanmar
Recurrences are recrudescence plus re-infections. AA=artesunate–amodiaquine. AL=artemether–lumefantrine. 
AM-F=ﬁ xed-dose artesunate–meﬂ oquine. AM-L=loose tablet regimen of artesunate–meﬂ oquine. 
DP=dihydroartemisinin–piperaquine.
Number at risk
AA 155 155 152 145 138 135 132 128 124 122 
AL 162 162 161 154 151 149 147 145 141 139
AM-F 169 169 165 165 165 164 161 160 159 157
AM-L 159 159 155 151 148 146 145 141 140 137
DP 160 160 159 158 156 152 148 146 143 140 
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Figure 3: Cumulative proportion of patients with vivax malaria during follow-up
AA=artesunate–amodiaquine. AL=artemether–lumefantrine. AM-F=ﬁ xed-dose artesunate–meﬂ oquine. 
AM-L=loose tablet regimen of artesunate–meﬂ oquine. DP=dihydroartemisinin–piperaquine. 
Number at risk
AA 155 155 152 144 137 134 124 103 90 77 
AL 162 162 161 151 137 116 94 79 69 64
AM-F 169 169 165 165 165 163 158 150 131 112
AM-L 159 159 155 150 145 134 122 104 90 77
DP 160 160 159 158 154 149 141 132 121 104 
Cu
m
ul
at
iv
e 
vi
va
x 
(%
)
50
60
40
30
20
10
0
0 3521147 49
Follow-up (days)
564228 63
AA
AL
AM-F
AM-L
DP
Articles
678 www.thelancet.com/infection   Vol 10   October 2010
aged 5–14 years (121 [41%] of 298) and in adults (97 [23%] 
of 423; p<0·0001). Independent of age, gametocytaemia 
was more common among moderately anaemic patients 
(haemoglobin <8·0 g/dL; 49 [70%] of 70) than among 
patients with higher values (215 [29%] of 738; RR 2·4, 
95% CI 2·0–2·9; p<0·0001). Without primaquine the 
treatment regimens had widely diﬀ erent gametocyte 
carriage rates (table 5). With primaquine all the 
treatment regimens had low gametocyte carriage, which 
overall was about 12-times lower than without (table 5; 
ﬁ gure 4). New gametocytaemia on day 7 was also 
reduced by primaquine (one of 272 vs ten of 268; 0·10, 
0·01–0·76; p=0.006).
246 patients (30%) had a haemoglobin concentration of 
less than 10·0 g/dL (mild anaemia), and 70 (9%) a 
concentration of less than 8·0 g/dL (moderate anaemia) at 
presentation. Young children were more likely to be 
anaemic at presentation (28 [32%] of 87) than older 
children (26 [9%] of 298) and adults (16 [4%] of 423; RR 5·5; 
95% CI 3·6–8·4; p<0·0001). On day 63, eight (1%) of 
693 patients were moderately anaemic and 72 (10%) were 
mildly anaemic. The mean increase of haemoglobin was 
similar among the ﬁ ve treatment groups, was unaﬀ ected 
by intercurrent P vivax, but was slightly reduced by 
primaquine (0·75 g/dL vs 1·04 g/dL; p=0·036; mean 
diﬀ erence 0·295 g/dL; 95% CI 0·199–0·570).
599 patients (74%) reported adverse events during the 
study (table 6). 13 patients (1·6%) vomited within the ﬁ rst 
hour (nine patients within 30 min and four within 
30–60 min), four after the loose tablet regimen of artesunate 
plus meﬂ oquine, three after artesunate–amodiaquine, two 
after artemether–lumefantrine, two after ﬁ xed-dose 
artesunate–meﬂ oquine, and two after dihydroartemisinin–
piperaquine. None vomited again after treatment was 
repeated. Dizziness was more common after ﬁ xed dose 
artesunate–meﬂ oquine than after artemether–lumefantrine 
(RR 1·24; 95% CI 1·03–1·48; p=0·03) and 
dihydroartemisinin–piperaquine (1·22; 1·02–1·45). Other 
side-eﬀ ects were less common and were not related to a 
speciﬁ c treatment. The only side-eﬀ ect attributable to 
primaquine was abdominal pain (table 7). There were no 
cases of urticaria or other potentially serious skin reactions, 
convulsions, behaviour disturbances, blackwater fever, or 
severe anaemia (<50 g/L).
Discussion
Control and ultimately elimination of falciparum malaria 
depends on providing eﬀ ective and well tolerated 
medicines and minimising transmission. In Myanmar, 
our large study shows that artesunate–meﬂ oquine, the 
ﬁ rst-line treatment in the main study region since 1996, 
remains very eﬀ ective. The new ﬁ xed-dose artesunate–
amodiaquine was well tolerated, but was not eﬀ ective 
enough to be recommended as a ﬁ rst-line treatment. 
The other available ACTs were all well tolerated and 
highly eﬀ ective, suggesting good adherence to the 
prescribed treatments, although only the ﬁ rst dose was 
observed (ie, the normal context of use). Addition of a 
single dose of primaquine to ACT regimens has a very 
large additional eﬀ ect on gametocytaemia, and therefore 
on malaria transmission potential, making any residual 
diﬀ erences in gametocyte carriage after the primary 
infection between the ﬁ ve ACT regimens insigniﬁ cant.
From an operational perspective, ﬁ xed-dose 
combinations are simple to give and avoid monotherapy, 
thereby protecting against resistance. Findings from 
our previous studies have shown that artesunate–
meﬂ oquine, the ﬁ rst-line treatment in Myanmar since 
1996, is very eﬀ ective.2–4,10 The new ﬁ xed-dose artesunate–
meﬂ oquine has the greatest eﬃ  cacy of all the ACTs 
After ACT 
(no 
primaquine)*
p value for 
comparison 
with AM-F
After ACT 
(with 
primaquine)*
p value for 
comparison 
with AM-F 
Artesunate–amodiaquine 94·4 <0·001 7·50 0·43
Artemether–lumefantrine 58·2 0·009 4·65 0·86
Artesunate–meﬂ oquine ﬁ xed-dose 29·2 ·· 4·02 ··
Artesunate–meﬂ oquine loose tablets 34·6 0·58 4·56 0·88
Dihydroartemisinin–piperaquine 112·8 <0·001 7·17 0·45
Total 65·51† 5·49†
ACT=artemisinin combination therapy. combination. *Person gametocytaemia weeks per 1000 person-weeks of 
follow-up. †Comparison of all patients receiving primaquine versus patients not receiving primaquine (rate ratio 11·9; 
95% CI 7·4–20·5; p≤0·0001).
Table 5: Plasmodium falciparum gametocyte carriage*
Number 
of 
patients
Number of 
P vivax 
infections
Proportion of 
P vivax infections by 
day 63 (95% CI)
p value for 
comparison 
with AM–L
p value for 
comparison 
with AM–F
Artesunate–amodiaquine
With P vivax at day 0 26 18 84 (66–96) 0·62 0·05
No P vivax at day 0 129 41 38 (30–48) 0·25 0·15
All 155 59 46 (38–55) 0·10 0·02
Artemether–lumefantrine
With P vivax at day 0 25 23 ··* <0·0001 <0·0001
No P vivax at day 0 137 62 49 (41–58) 0·03 <0·0001
All 162 85 57 (49–65) 0·004 <0·0001
Artesunate–meﬂ oquine (ﬁ xed dose)
With P vivax at day 0 21 11 55 (35–77) 0·01 ··
No P vivax at day 0 148 44 31 (24–40) 0·01 ··
All 169 55 34 (28–42) <0·001 ··
Artesunate–meﬂ oquine (loose)
With P vivax at day 0 31 28 93 (81–99) ·· 0·01
No P vivax at day 0 130 47 42 (33–51) ·· 0·01
 All 161 75 53 (45–61) ·· 0·0001
Dihydroartemisinin–piperaquine
With P vivax at day 0 26 15 68 (49–86) 0·01 0·69
No P vivax at day 0 135 41 34 (26–43) 0·02 0·93
All 161 56 39 (32–48) <0·001 0·67
AM-F=artesunate–meﬂ oquine ﬁ xed-dose combination. AM-L=artesunate–meﬂ oquine loose tablets. *Day 63 rate 
could not be calculated because all patients either lost to follow-up or relapsed by day 56.
Table 4: Intercurrent Plasmodium vivax infections
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assessed.5 Artesunate–meﬂ oquine regimens were also 
associated with greater post-treatment prophylaxis than 
the other drugs,12 although diﬀ erences with 
dihydroartemisinin–piperaquine were not signiﬁ cant. 
Although artesunate–meﬂ oquine regimens were 
associated with slightly more dizziness than were ﬁ xed-
dose artemether–lumefantrine or dihydro artemisinin–
piperaquine,2–4,9,10,13,14 high cure rates argue against a 
signiﬁ cant eﬀ ect on adherence.
Malaria transmission in Myanmar is seasonal and 
generally low, but access to eﬀ ective drugs is limited, 
and the clinical epidemiology is similar to that of 
higher-transmission settings with a high prevalence of 
anaemia, high rates of P falciparum gametocytaemia, 
and substantial discrepancy between cure rates in 
adults and children.2–4,10 The artemisinin component of 
ACTs reduces gametocyte carriage,6,7,15 and patients who 
received artesunate–meﬂ oquine regimens had the 
lowest rates of gametocyte carriage after treatment, 
probably because of the higher dose of the artemisinin 
derivative compared with artemether–lumefantrine 
and dihydroartemisinin–piperaquine, and the greater 
antimalarial eﬀ ect of meﬂ oquine compared with 
amodiaquine. The use of ACTs in parts of Rakhine state 
since 19962–4,10 has resulted in a gradual but substantial 
decrease in falciparum malaria in regions where the 
drugs are available. The high gametocyte carriage rates 
probably contribute to diﬀ erences in the eﬀ ect of ACTs 
on malaria transmission and thus incidence in 
Myanmar compared with that in other areas in the 
region, such as the western border of Thailand, where 
gametocyte carriage rates are low, treatment delays are 
brief, and, as a result of ACT deployment, falciparum 
malaria incidence has fallen substantially.16 Greater 
coverage of eﬀ ective drug treatments with more potent 
transmission-blocking activity is expected to result in 
greater eﬀ ects on malaria incidence.
The 8-aminoquinolines have a rapid and powerful 
sterilising eﬀ ect on mature gametocytes.17,18 Single-dose 
primaquine has been widely recommended in the past, 
and used extensively in eradication campaigns; however, 
its safety proﬁ le has not been well characterised.19 
Primaquine causes abdominal discomfort, particularly if 
taken on an empty stomach, and potentially serious 
haemolytic anaemia in patients with glucose-6-phosphate 
dehydrogenase (G6PD) deﬁ ciency.20 Single doses have 
been judged safe, particularly when prevalent genotypes 
confer mild G6PD deﬁ ciency, although a recent study has 
challenged this assumption.21 In our study there were no 
severe episodes of haemolysis, although we did note a 
small but signiﬁ cant adverse eﬀ ect on recovery from 
anaemia. We did not test for G6PD deﬁ ciency, and more 
frequent measurements of haemoglobin concentrations 
were not possible.
Mixed P falciparum and P vivax infections were 
common. 330 patients (41%) had at least one episode of 
vivax malaria in the 63 day follow-up. The risk was 
With primaquine (n=397) No primaquine (n=411) Total (n=808) p value*
Dizziness 239 (60%) 240 (58%) 479 (59%) 0·61
Nausea 78 (20%) 68 (17%) 146 (18%) 0·26
Anorexia 48 (12%) 66 (16%) 114 (14%) 0·11
Diarrhoea 31 (8%) 45 (11%) 76 (9%) 0·13
Abdominal pain 64 (16%) 47 (11%) 111 (14%) 0·05
Palpitations 86 (22%) 85 (21%) 171 (21%) 0·73
Sleeplessness 50 (13%) 53 (13%) 103 (13%) 0·90
Headache 4 (1%) 2 (1%) 6 (1%) 0·44†
Vomiting in 
ﬁ rst 24 h
25 (6%) 23 (6%) 48 (6%) 0·69
*For comparison between primaquine allocation, adjusted for treatment groups. †p value not adjusted for diﬀ erences 
between treatment groups. 
Table 7: Number of patients reporting side-eﬀ ects after treatment with primaquine
AA 
(n=155)
AL 
(n=162)
AM-F 
(n=169)
AM-L 
(n=161)
DP 
(n=161)
Total 
(n=808)
p value*
Dizziness 91 (59%) 86 (53%) 111 (66%) 104 (65%) 87 (54%) 479 (59%) 0·06
Nausea 27 (17%) 28 (17%) 33 (20%) 30 (19%) 28 (17%) 146 (18%) 0·98
Anorexia 29 (19%) 17 (11%) 25 (15%) 21 (13%) 22 (14%) 114 (14%) 0·34
Diarrhoea 17 (11%) 12 (7%) 11 (7%) 16 (10%) 20 (12%) 76 (9%) 0·32
Abdominal pain 20 (13%) 23 (14%) 23 (14%) 26 (16%) 19 (12%) 111 (14%) 0·83
Palpitations 35 (23%) 25 (15%) 38 (23%) 41 (26%) 32 (20%) 171 (21%) 0·23
Sleeplessness 22 (14%) 14 (9%) 25 (15%) 24 (15%) 18 (11%) 103 (13%) 0·33
Headache 2 (1%) 2 (1%) 0 0 2 (1%) 6 (1%) 0·38†
Vomiting in 
ﬁ rst 24 h
7 (5%) 6 (4%) 9 (5%) 16 (10%) 10 (6%) 48 (6%) 0·18
AA=artesunate–amodiaquine. AL=artemether–lumefantrine. AM-F=artesunate–meﬂ oquine ﬁ xed-dose combination. 
AM-L=artesunate–meﬂ oquine loose tablets. DP=dihydroartemisinin–piperaquine. *For comparison of frequency across 
the ﬁ ve treatment groups, adjusted for primaquine allocation. †p value for diﬀ erences between treatment groups not 
adjusted for primaquine allocation. 
Table 6: Number of patients reporting side-eﬀ ects at least once during study
Figure 4: Eﬀ ects of a single dose of primaquine on Plasmodium falciparum gametocyte carriage after 
artemisinin combination treatment
All ﬁ ve ACT regimens pooled. No gametocytaemia was detected after day 42.
Pa
tie
nt
s w
ith
 g
am
et
oc
yt
ae
m
ia
 (%
)
40
30
20
10
0
0 3521147
Follow-up (days)
4228
No primaquine
Primaquine
Articles
680 www.thelancet.com/infection   Vol 10   October 2010
particularly high in young children—56 children (64%) 
younger than 5 years had vivax malaria after acute 
falciparum malaria. This compares with P falciparum 
recrudescence rates of less than 10%. Treatment of vivax 
relapses with chloroquine might have provided weak 
additional activity against P falciparum, suppressing 
some late recrudescence, particularly for the less 
eﬀ ective artesunate–amodiaquine. Although because 
most recrudescence happened within 4 weeks, and 
most vivax infections were not noted until after 5 weeks, 
this eﬀ ect is unlikely to have been large. Thus for the 
four highly eﬀ ective ACT regimens the main clinical 
problem after eﬀ ective treatment of acute falciparum 
malaria in Myanmar is recurrent P vivax malaria not 
P falciparum.22 Recurrence of vivax malaria was over 
four times more likely than was recurrence of 
falciparum malaria, emphasising the public health 
importance of vivax infections after falciparum malaria. 
If safe radical treatment was available, then these very 
high rates would argue for radical treatment of all 
malaria in this region where mixed infections are 
so common.
This is, to our knowledge, the ﬁ rst comparison of all 
currently available ﬁ xed-dose artemisinin combination 
treatments for falciparum malaria. Our ﬁ ndings 
suggest that artesunate–meﬂ oquine, artemether–
lumefantrine, or dihydroartemisinin–piperaquine are 
all good treatments of falciparum malaria in Myanmar. 
The new ﬁ xed dose artesunate–meﬂ oquine had the 
highest cure rates, the lowest rates of gametocyte 
carriage, and the most eﬀ ective suppression of P vivax 
malaria. Adverse eﬀ ects were generally mild, despite 
the high doses received by some patients, and did not 
substantially aﬀ ect adherence. Although giving the 
entire 25 mg/kg dose of meﬂ oquine as loose tablets 
was directly observed, suppression of recurrent vivax 
malaria was signiﬁ cantly worse than with the ﬁ xed 
combination, suggesting better absorption of 
meﬂ oquine with the latter.5,23,24 The addition of a single 
gametocytocidal dose of primaquine was well tolerated 
and highly eﬀ ective and did not cause serious adverse 
eﬀ ects, although more studies to characterise the safety 
with diﬀ erent G6PD deﬁ ciency genotypes are needed. 
The addition of a single dose of primaquine to ACTs 
could have a major eﬀ ect on malaria transmission from 
treated patients, and could have a crucial role in 
elimination programmes.25
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